Femasys vs Lucid Diagnostics
Lucid Diagnostics reported revenue of $5 million in fiscal 2025, 2.0 times Femasys' $2 million in fiscal 2025. Femasys' revenue grew 40.8% in its latest year, and Lucid Diagnostics' grew 8.3%. Femasys had an operating margin of -767.0%, against -1054.8% at Lucid Diagnostics. Free cash flow was −$19 million at Femasys and −$47 million at Lucid Diagnostics.
Side by side
| Femasys | Lucid Diagnostics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $5M |
| Revenue growth | 40.8% | 8.3% |
| Revenue growth a year, last 5 years | 18.1% | — |
| Gross margin | 62.0% | −41.7% |
| Operating margin | −767.0% | −1,054.8% |
| Net margin | −812.3% | −1,232.7% |
| Free cash flow | −$19M | −$47M |
| Free cash flow margin | −837.9% | −992.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 77.6% | 101.8% |
| Last close | $1.26 | $0.39 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $74,000, sold $0 | bought $245,000, sold $0 |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
FemasysLucid Diagnostics
Operating margin
Percent of revenue
FemasysLucid Diagnostics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
FemasysLucid Diagnostics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Femasys and Lucid Diagnostics pages.